Georgia Mitsa
YOU?
Author Swipe
View article: Supplementary Data Table T2 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies
Supplementary Data Table T2 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies Open
LFQ data DCIS vs IDC
View article: Supplementary Data Table T5 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies
Supplementary Data Table T5 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies Open
PRM data DCIS vs IDC
View article: Supplementary Data Table T1 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies
Supplementary Data Table T1 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies Open
Anonymized Clinical Data
View article: Supplementary Data Table T3 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies
Supplementary Data Table T3 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies Open
LFQ data DCIS mixed vs IDC mixed
View article: Supplementary Data Table T4 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies
Supplementary Data Table T4 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies Open
LFQ data DCIS paired vs IDC paired
View article: Supplementary Table S3 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors
Supplementary Table S3 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors Open
Detailed results of pathway mapping by Qiagen IPA
View article: Supplementary Table S2 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors
Supplementary Table S2 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors Open
Proteins expression differences between capivasertib-resistant vs. capivasertib-sensitive cells quantified by validated MRM-MS assays as compared to the profile observed in patient samples
View article: Supplementary Methods S1 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors
Supplementary Methods S1 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors Open
Supplemental Materials and Methods concerning patient samples, cell lines, tissue culture, iMALDI-MS, Nano-LC-Orbitrap-MS, LC-MRM-MS
View article: Supplementary Validation Data S1 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors
Supplementary Validation Data S1 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors Open
Supplementary Validation Data demonstrating the performance of the iMALDI-MS assay
View article: Supplementary Figure S2 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors
Supplementary Figure S2 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors Open
Individual protein concentrations measured by iMALDI-MS for PTEN vs. IHC H-score
View article: Supplementary Validation Data S2 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors
Supplementary Validation Data S2 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors Open
Quality Assessment of the Global Proteomics Data
View article: Supplementary Figure S3 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors
Supplementary Figure S3 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors Open
Comparison of iMALDI and Global Proteomics results for primary vs metastatic samples
View article: Supplementary Figure S4 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors
Supplementary Figure S4 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors Open
Combination treatment of cell lines with capivasertib and an eIF2α inhibitor
View article: Supplementary Table S1 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors
Supplementary Table S1 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors Open
Detailed results of the label-free quantitation
View article: Supplementary Figure S1 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors
Supplementary Figure S1 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors Open
Individual protein concentrations measured by iMALDI-MS for each sample, comparison of measured PTEN concentration to IHC H-score
View article: Data from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies
Data from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies Open
Ductal carcinoma in situ (DCIS) is the most common type (80%) of noninvasive breast lesions in women. The lack of validated prognostic markers, limited patient numbers, and variable tissue quality have a significant impact on the di…
View article: Figure 3 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies
Figure 3 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies Open
Differential expression analysis reflects loss of basal membrane stability, inflammatory processes, and epithelial–mesenchymal transition as key events toward DCIS to IDC progression. A, Volcano plot of the proteome of IDC compared …
View article: Figure 2 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies
Figure 2 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies Open
Data quality and evaluation of variability. A, Dynamic range of ∼2,860 proteins quantified in ductal breast cancer, at a 1% FDR. All −log10 values were based on NSAF values, which were used to normalize the spectral count…
View article: Supplementary Data Table T1 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies
Supplementary Data Table T1 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies Open
Anonymized Clinical Data
View article: Supplementary Data Table T3 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies
Supplementary Data Table T3 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies Open
LFQ data DCIS mixed vs IDC mixed
View article: Supplementary Data Table T4 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies
Supplementary Data Table T4 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies Open
LFQ data DCIS paired vs IDC paired
View article: Supplementary Data Table T5 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies
Supplementary Data Table T5 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies Open
PRM data DCIS vs IDC
View article: Table 2 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies
Table 2 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies Open
List of putative metabolic biomarkers identified by artificial intelligence–based metabolic profiling (inferred from proteomics data) of DCIS and IDC specimens from the same patient
View article: Supplementary Data Table T2 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies
Supplementary Data Table T2 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies Open
LFQ data DCIS vs IDC
View article: Figure 4 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies
Figure 4 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies Open
Dysregulation of central energy metabolism is a key event in the DCIS tumor phenotype. A, Graphical representation of hallmarks of cancer [modified from (82)] characteristic for proteomic tumor profiling of DCIS and IDC tumors. B…
View article: Table 1 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies
Table 1 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies Open
Overlapping molecules from independent gene expression studies and this proteomic profiling
View article: Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies
Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies Open
Ductal carcinoma in situ (DCIS) is the most common type (80%) of noninvasive breast lesions in women. The lack of validated prognostic markers, limited patient numbers, and variable tissue quality have a significant impact on the diagnosis…
View article: Supplementary Figure S4 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors
Supplementary Figure S4 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors Open
Combination treatment of cell lines with capivasertib and an eIF2α inhibitor
View article: Supplementary Figure S1 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors
Supplementary Figure S1 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors Open
Individual protein concentrations measured by iMALDI-MS for each sample, comparison of measured PTEN concentration to IHC H-score
View article: Supplementary Table S3 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors
Supplementary Table S3 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors Open
Detailed results of pathway mapping by Qiagen IPA